Stay updated with breaking news from Initial Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle - -
Skinvisible Announces Significant Progress in Licensee's Clinical Trials ...
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in patients with Graves' disease. Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). The company says the results show that batoclimab meaningfully exceeded 50% response rates. Consistent with studies of batoclimab in other indications, 680 mg administered subcutaneously (SC) in t
TFF Pharmaceuticals, Inc. (TFFP), the developer of drug products based on Thin Film Freezing technology platform, announced Tuesday positive initial data from its ongoing Phase 2 trials of TFF VORI and TFF TAC, along with clinical data from the ongoing TFF VORI Expanded Access Program or EAP.
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not...